Cognitive function testing in adult brain tumor trials: lessons from a comprehensive review

2012 ◽  
Vol 12 (5) ◽  
pp. 655-667 ◽  
Author(s):  
Chip Caine ◽  
Minesh P Mehta ◽  
Nadia N Laack ◽  
Vinai Gondi
Keyword(s):  
Brain Tumor ◽  
Cognitive Function ◽  
Adult Brain ◽  
Comprehensive Review ◽  
Function Testing

scholarly journals P05.01 the efficacy of donepezil on cognitive function in postoperative brain tumor patients

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii33-iii34
Author(s):  
Y Diansari ◽  
Y Harun ◽  
S Marisdina ◽  
Y Felistia
Keyword(s):  
Cognitive Impairment ◽  
Brain Tumor ◽  
Cognitive Function ◽  
Acetylcholinesterase Inhibitor ◽  
Primary Brain Tumor ◽  
Adult Brain ◽  
Cognitive Domain ◽  
Cognitive Test ◽  
Tumor Patients ◽  
Old Patients

Abstract BACKGROUND Cognitive impairment is frequently found in brain tumor patients. More than 90% of patients with brain tumor have at least one cognitive domain disturbance. Decline in cognitive function could happen before due to the tumor or after the treatment because of surgery, radiotherapy or chemotherapy. Until now there is no available standard treatment for patients with cognitive impairment due to brain tumor. Moreover, Donepezil is an acetylcholinesterase inhibitor known to be useful for improving cognitive function in patients with dementia. This clinical study aims to determine the cognitive effects of donepezil therapy in patients with brain tumors following surgery. MATERIAL AND METHODS This is a pilot study with total of 20 adult brain tumor patients were double blinded randomly assigned to receive a single daily dose (5mg for 12 weeks) of donepezil or placebo. The inclusion criteria were patients with primary brain tumor who had undergone surgery with cognitive impairment at the initial evaluation and age range 18 to 65 years old. Patients with previous cognitive problem, other diseases that can cause cognitive decline e.g. stroke and history of taking donepezil, memantine, methylphenidate, ginkgo biloba, and modafinil were excluded. A cognitive test using Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment Indonesia Version (MoCA-INA) assessing memory, attention, language, visuospatial, verbal fluency, and executive functions were administered before random assignment and at 4, 8 and 12 weeks. A cognitive composite score (primary outcome) and individual cognitive domains were evaluated. Furthermore, side effects and adverse events were also recorded. RESULTS Of this mostly middle-age (30–60 years old), female, meningioma as primary brain tumor with frontal and temporal lobe are the most frequent locations. After 12 weeks of treatment, the composite scores did differ significantly between groups (MMSE P=0.027, MoCA-INA P=0.024). Furthermore, the significant differences favouring donepezil were observed for orientation and recall domains using MMSE with p value 0.017 and 0.006 respectively. Visuospatial (P=0.034) and delayed recall domains (P=0.004) were significant through MoCA-INA evaluation. In addition, Mean MMSE score for pre-donepezil administration was 14.60 ± 4.47 and after 3 months was 20.40 ± 4.24 (P=0.000). Mean MoCA-INA score for pre-donepezil administration was 9.30 ± 3.65 and after 3 months was 15.30 ± 4.24 (P=0.000). However, there was no differences in the placebo group (MMSE P= 0.066, MoCA-INA P=0.313). CONCLUSION Three months treatment with donepezil significantly improve the cognitive functions among post-operative brain tumor patients with no reported side effect. Moreover, further research is needed for longer duration of follow-up and possibility of increased doses.

scholarly journals Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial

2015 ◽  
Vol 33 (15) ◽  
pp. 1653-1659 ◽  
Author(s):  
Stephen R. Rapp ◽  
L. Doug Case ◽  
Ann Peiffer ◽  
Michelle M. Naughton ◽  
Michael D. Chan ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Cognitive Function ◽  
Adult Brain ◽  
Composite Score ◽  
Phase Iii ◽  
Cognitive Test ◽  
Controlled Clinical Trial ◽  
Motor Speed ◽  
Whole Brain Irradiation ◽  
Brain Irradiation

Purpose Neurotoxic effects of brain irradiation include cognitive impairment in 50% to 90% of patients. Prior studies have suggested that donepezil, a neurotransmitter modulator, may improve cognitive function. Patients and Methods A total of 198 adult brain tumor survivors ≥ 6 months after partial- or whole-brain irradiation were randomly assigned to receive a single daily dose (5 mg for 6 weeks, 10 mg for 18 weeks) of donepezil or placebo. A cognitive test battery assessing memory, attention, language, visuomotor, verbal fluency, and executive functions was administered before random assignment and at 12 and 24 weeks. A cognitive composite score (primary outcome) and individual cognitive domains were evaluated. Results Of this mostly middle-age, married, non-Hispanic white sample, 66% had primary brain tumors, 27% had brain metastases, and 8% underwent prophylactic cranial irradiation. After 24 weeks of treatment, the composite scores did not differ significantly between groups (P = .48); however, significant differences favoring donepezil were observed for memory (recognition, P = .027; discrimination, P = .007) and motor speed and dexterity (P = .016). Significant interactions between pretreatment cognitive function and treatment were found for cognitive composite (P = .01), immediate recall (P = .05), delayed recall (P = .004), attention (P = .01), visuomotor skills (P = .02), and motor speed and dexterity (P < .001), with the benefits of donepezil greater for those who were more cognitively impaired before study treatment. Conclusion Treatment with donepezil did not significantly improve the overall composite score, but it did result in modest improvements in several cognitive functions, especially among patients with greater pretreatment impairments.

scholarly journals Mapping of long-term cognitive and motor deficits in pediatric cerebellar brain tumor survivors into a cerebellar white matter atlas

2021 ◽  
Author(s):  
Frederik Grosse ◽  
Stefan Mark Rueckriegel ◽  
Ulrich-Wilhelm Thomale ◽  
Pablo Hernáiz Driever
Keyword(s):  
Brain Tumor ◽  
Executive Function ◽  
Cognitive Function ◽  
White Matter ◽  
Cerebellar Nuclei ◽  
Motor Deficits ◽  
Deep Cerebellar Nuclei ◽  
Cerebellar White Matter ◽  
Lesion Symptom Mapping

Abstract Purpose Diaschisis of cerebrocerebellar loops contributes to cognitive and motor deficits in pediatric cerebellar brain tumor survivors. We used a cerebellar white matter atlas and hypothesized that lesion symptom mapping may reveal the critical lesions of cerebellar tracts. Methods We examined 31 long-term survivors of pediatric posterior fossa tumors (13 pilocytic astrocytoma, 18 medulloblastoma). Patients underwent neuronal imaging, examination for ataxia, fine motor and cognitive function, planning abilities, and executive function. Individual consolidated cerebellar lesions were drawn manually onto patients’ individual MRI and normalized into Montreal Neurologic Institute (MNI) space for further analysis with voxel-based lesion symptom mapping. Results Lesion symptom mapping linked deficits of motor function to the superior cerebellar peduncle (SCP), deep cerebellar nuclei (interposed nucleus (IN), fastigial nucleus (FN), ventromedial dentate nucleus (DN)), and inferior vermis (VIIIa, VIIIb, IX, X). Statistical maps of deficits of intelligence and executive function mapped with minor variations to the same cerebellar structures. Conclusion We identified lesions to the SCP next to deep cerebellar nuclei as critical for limiting both motor and cognitive function in pediatric cerebellar tumor survivors. Future strategies safeguarding motor and cognitive function will have to identify patients preoperatively at risk for damage to these critical structures and adapt multimodal therapeutic options accordingly.

scholarly journals Impact of COVID‐19 on adolescent and emerging adult brain tumor survivors and their parents

2021 ◽  
Author(s):  
Allison P. Fisher ◽  
Jamie Patronick ◽  
Cynthia A. Gerhardt ◽  
Krestin Radonovich ◽  
Ralph Salloum ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Emerging Adult ◽  
Adult Brain

Cognitive Function Testing in Comprehensive Geriatric Assessment

1990 ◽  
Vol 38 (10) ◽  
pp. 1088-1092 ◽  
Author(s):  
Harold W. Ward ◽  
Joe W. Ramsdell ◽  
J. Edward Jackson ◽  
Marian Renvall ◽  
Jo Anne Swart ◽  
...  
Keyword(s):  
Cognitive Function ◽  
Geriatric Assessment ◽  
Comprehensive Geriatric Assessment ◽  
Function Testing

Rehabilitation pathways in adult brain tumor patients in the first 12 months of disease. A retrospective analysis of services utilization in 719 patients

2016 ◽  
Vol 24 (11) ◽  
pp. 4801-4806 ◽  
Author(s):  
Andrea Pace ◽  
Veronica Villani ◽  
Cristiano Parisi ◽  
Stefano Di Felice ◽  
Margaux Lamaro ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Retrospective Analysis ◽  
Adult Brain ◽  
Tumor Patients ◽  
Services Utilization

scholarly journals Quality of Life Among Parents of Adolescent and Young Adult Brain Tumor Survivors

2017 ◽  
Vol 39 (8) ◽  
pp. 579-584 ◽  
Author(s):  
David K. Buchbinder ◽  
Michelle A. Fortier ◽  
Kathryn Osann ◽  
Justin Wilford ◽  
Violet Shen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Brain Tumor ◽  
Young Adult ◽  
Adult Brain ◽  
Adolescent And Young Adult
Sign in / Sign up

Export Citation Format

Share Document